Selenium Supplementation Does Not Lower Likelihood of Bladder Cancer Recurrence

Share this content:
Among patients with non-invasive urothelial carcinoma, oral supplementation with selenium does not lower the likelihood of recurrence.
Among patients with non-invasive urothelial carcinoma, oral supplementation with selenium does not lower the likelihood of recurrence.

Among patients with non-invasive urothelial carcinoma, oral supplementation with selenium does not lower the likelihood of recurrence, according to a study published in the European Journal of Cancer.1

Researchers from Belgium evaluated results from the phase 3, placebo-controlled, randomized SELEBLAT (Selenium and Bladder Cancer Trial; ClinicalTrials.gov Identifier: NCT00729287), which included 14 Belgian hospitals, to examine if supplementation with selenium had an effect on the recurrence of non-invasive urothelial carcinoma.

“Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of bladder cancer,” the authors note. “We therefore hypothesized that selenium may be suitable for chemoprevention of recurrence of bladder cancer.”

In total, 151 patients received selenium yeast 200 μg and 141 received placebo. Each patient underwent treatment once a day for 3 years along with standard care.

RELATED: Optimal Timing for Re-resection in Incidental Gallbladder Cancer Evaluated

Upon intention to treat analysis, the researchers found that 43 patients had disease recurrence in the selenium group, while 45 had recurrence in the placebo group. With a hazard ratio of 0.85, the hazard ratio upon per protocol analysis showed 42 recurrences with selenium and 39 with placebo.

Reference

  1. Goossens ME, Zeegers MP, van Poppel H, et al. Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. Eur J Cancer. 2016 Oct 28. doi: 10.1016/j.ejca.2016.09.021 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters